# Cerebrolysin REGistry Study in Stroke

> **NCT02541227** · — · TERMINATED · sponsor: **Ever Neuro Pharma GmbH** · enrollment: 1823 (actual)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** Cerebrolysin

## Key facts

- **NCT ID:** NCT02541227
- **Lead sponsor:** Ever Neuro Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05
- **Primary completion:** 2017-12
- **Final completion:** 2021-12
- **Target enrollment:** 1823 (ACTUAL)
- **Why stopped:** The goal to match 1000 patients per group could not be achieved with reasonable effort and in reasonable time.
- **Last updated:** 2022-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02541227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02541227, "Cerebrolysin REGistry Study in Stroke". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02541227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*